Renovaro (RENB) Competitors $1.64 +0.10 (+6.15%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RENB vs. UPB, COLL, SEPN, BCAX, ZYME, GYRE, LQDA, PCRX, PAHC, and COGTShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Upstream Bio (UPB), Collegium Pharmaceutical (COLL), Septerna (SEPN), Bicara Therapeutics (BCAX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Liquidia (LQDA), Pacira BioSciences (PCRX), Phibro Animal Health (PAHC), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical preparations" industry. Renovaro vs. Upstream Bio Collegium Pharmaceutical Septerna Bicara Therapeutics Zymeworks Gyre Therapeutics Liquidia Pacira BioSciences Phibro Animal Health Cogent Biosciences Renovaro (NASDAQ:RENB) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends. Does the media favor RENB or UPB? In the previous week, Upstream Bio had 1 more articles in the media than Renovaro. MarketBeat recorded 7 mentions for Upstream Bio and 6 mentions for Renovaro. Upstream Bio's average media sentiment score of 0.40 beat Renovaro's score of 0.28 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Renovaro 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upstream Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer RENB or UPB? Upstream Bio has a consensus target price of $56.50, indicating a potential upside of 248.55%. Given Upstream Bio's stronger consensus rating and higher possible upside, analysts plainly believe Upstream Bio is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in RENB or UPB? 71.4% of Renovaro shares are held by institutional investors. 21.7% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor RENB or UPB? Upstream Bio received 4 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformRenovaroN/AN/AUpstream BioOutperform Votes4100.00% Underperform VotesNo Votes Which has stronger valuation & earnings, RENB or UPB? Upstream Bio has higher revenue and earnings than Renovaro. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$80.65M-$0.96-1.71Upstream Bio$2.21M393.66N/AN/AN/A Is RENB or UPB more profitable? Upstream Bio's return on equity of 0.00% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -67.54% -52.89% Upstream Bio N/A N/A N/A SummaryUpstream Bio beats Renovaro on 9 of the 11 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$260.30M$6.57B$5.10B$9.07BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-1.7110.5591.0817.15Price / SalesN/A195.381,113.51116.81Price / CashN/A57.1642.2637.86Price / Book1.845.104.784.78Net Income-$80.65M$151.51M$119.77M$225.60M7 Day Performance-6.82%-2.12%-1.87%-1.23%1 Month Performance227.48%-3.11%11.46%3.07%1 Year Performance-50.90%11.52%30.53%16.48% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro1.1855 of 5 stars$1.64+6.1%N/A-50.5%$260.30MN/A-1.7112News CoverageGap UpHigh Trading VolumeUPBUpstream Bio2.0497 of 5 stars$19.12-5.6%$56.50+195.5%N/A$1.02BN/A0.0038COLLCollegium Pharmaceutical3.8414 of 5 stars$30.68+2.0%$42.60+38.9%-0.4%$989.43M$599.25M12.97210News CoveragePositive NewsSEPNSepterna2.2189 of 5 stars$21.83-2.5%$43.67+100.0%N/A$969.25MN/A0.00N/ABCAXBicara TherapeuticsN/A$17.53+0.2%$43.00+145.3%N/A$953.91MN/A0.0032News CoverageGap DownZYMEZymeworks2.8055 of 5 stars$13.83+9.9%$18.83+36.2%+52.5%$952.61M$76.01M-9.25290Analyst ForecastNews CoverageGap DownGYREGyre Therapeutics0.6053 of 5 stars$10.04+4.1%N/A-61.2%$938.95M$105.03M0.0040News CoveragePositive NewsLQDALiquidia3.4225 of 5 stars$11.07+1.4%$24.00+116.8%+3.7%$936.93M$15.61M-6.7050Analyst ForecastNews CoveragePCRXPacira BioSciences3.7422 of 5 stars$19.99+0.7%$23.50+17.6%-41.1%$922.94M$674.98M-9.78720Gap DownPAHCPhibro Animal Health4.1314 of 5 stars$22.74+0.3%$19.00-16.4%+89.6%$921.04M$1.05B52.561,940Analyst ForecastCOGTCogent Biosciences1.9533 of 5 stars$8.29+1.7%$14.83+78.9%+51.9%$915.71MN/A-3.2980 Related Companies and Tools Related Companies Upstream Bio Alternatives Collegium Pharmaceutical Alternatives Septerna Alternatives Bicara Therapeutics Alternatives Zymeworks Alternatives Gyre Therapeutics Alternatives Liquidia Alternatives Pacira BioSciences Alternatives Phibro Animal Health Alternatives Cogent Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RENB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
